0.5935

0.15% +0.0009

Bionexus Gene Lab Corp (BGLC)

Overview News Price History Discussions Forecast

Bionexus Gene Lab Corp stock is currently priced at $0.5935, with a 24-hour trading volume of 37,825. It has seen a +0.15% increased in the last 24 hours and a -14.97% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.5992 pivot point. If it approaches the $0.5734 support level, significant changes may occur.

Previous Close:

$0.5926

Open:

$0.5845

24h Volume:

37,825

Market Cap:

$10.49M

Revenue:

$10.34M

Net Income/Loss:

$-3.09M

P/E Ratio:

EPS:

Net Cash Flow:

$-736.20K

1W Performance:

-1.05%

1M Performance:

-14.97%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$0.5845

$0.6199

52W Range:

$0.4004

$3.39

Bionexus Gene Lab Corp Stock (BGLC) Company Profile

Name

Bionexus Gene Lab Corp

Sector

Basic Materials (266)

Industry

Specialty Chemicals (65)

Phone

60122126512

Address

10-2 TOWER B, VERTICAL BUSINESS SUITE,, KUALA LUMPUR

Employee

Twitter

Next Earnings Date

Latest SEC Filings

BGLC's Discussions on Twitter

Bionexus Gene Lab Corp Stock (BGLC) Latest News

BioNexus Gene Lab Corp. Bersetuju untuk Melabur RM 1.2 juta dalam Ascension Innovation (AISB) untuk Memajukan Inovasi Kesihatan Digital menerusi penerimaan AI dalam Penjagaan Kesihatan

GlobeNewswire Inc.

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

GlobeNewswire Inc.

Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why Robinhood Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Benzinga

Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Dow Dips Over 300 Points; US Annual Inflation Slows to 3.1% In January

Benzinga

Bionexus Gene Lab Corp Stock (BGLC) Financials Data

Bionexus Gene Lab Corp (BGLC) Revenue 2024

BGLC reported a revenue (TTM) of $10.34 million for the quarter ending September 30, 2023, a -8.80% decline year-over-year.

Bionexus Gene Lab Corp (BGLC) Net Income 2024

BGLC net income (TTM) was -$3.09 million for the quarter ending September 30, 2023, a -2,717% decrease year-over-year.

Bionexus Gene Lab Corp (BGLC) Cash Flow 2024

BGLC recorded a free cash flow (TTM) of -$736.20 thousand for the quarter ending September 30, 2023, a -241.66% decrease year-over-year.

Bionexus Gene Lab Corp (BGLC) Earnings per Share 2024

BGLC earnings per share (TTM) was -$0.273 for the quarter ending September 30, 2023, a -2,138% decline year-over-year.

BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.